Sitagliptin Associated Pancreatic Carcinoma: a Review of the FDA AERS Database

Authors

Angela Nagel, St. John Fisher UniversityFollow
Gabriela Cipriano, St. John Fisher UniversityFollow
Nabila Ahmed-Sarwar, St. John Fisher UniversityFollow
Robbert Van Manen, Oracle Health Sciences ConnectFollow
Jack Brown, St. John Fisher University

Document Type

Poster Presentation

Publication Date

10-14-2014

Keywords

fsc2015

Abstract

Purpose: Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus in adults, as adjunct to diet and exercise to improve glycemic control. During phase III studies, sitagliptin was shown to cause toxicity to the pancreas, including pancreatitis. To date there is limited information available regarding its association with pancreatic carcinoma. Our goal was to qualitatively and quantitatively review available information in the AERS database in order to provide clinicians with a general understanding of the comparative occurrence of sitagliptin use and pancreatic carcinoma and any clinically relevant characteristics that may be useful in identifying patients at risk.

Comments

Presented at the American College of Clinical Pharmacy Annual Meeting in Austin, Texas, October 14, 2014.

Publication Information

Nagel, Angela; Cipriano, Gabriela; Ahmed-Sarwar, Nabila; Van Manen, Robbert; and Brown, Jack, "Sitagliptin Associated Pancreatic Carcinoma: a Review of the FDA AERS Database" (2014). Pharmacy Faculty/Staff Publications. Paper 52.
https://fisherpub.sjf.edu/pharmacy_facpub/52

Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.